Prognostic Value of Contrast-enhanced Cardiac Magnetic Resonance Imaging in Patients with Newly Diagnosed Non-Ischemic Cardiomyopathy: Cohort Study

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Müller, Karin A L ^a   Müller, Iris ^a   Kramer, Ulrich ^b   Kandolf, Reinhard ^a   Gawaz, Meinrad ^a   Bauer, Axel ^a   Zuern, Christine S ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GADOBUTROL; TROPONIN I;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART TRANSPLANTATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NONISCHEMIC CARDIOMYOPATHY; PREDICTION; PROGNOSIS; QRS COMPLEX; RISK ASSESSMENT; SUDDEN DEATH; SURVIVAL RATE;

ADULT; AGED; CARDIOMYOPATHIES; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 84874248698     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057077     Document Type: Article

References (37)

1. D'Ambrosio A, Patti G, Manzoli A, Sinagra G, Di Lenarda A, et al. (2001) The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 85: 499-504.
2. Jefferies JL, Towbin JA, (2010) Dilated cardiomyopathy. Lancet 375: 752-762.
3. Maron BJ, (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA: the journal of the American Medical Association 287: 1308-1320.
4. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, et al. (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New England journal of medicine 352: 1539-1549.
5. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, et al. (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. The New England journal of medicine 350: 2140-2150.
6. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, et al. (2009) Advanced heart failure treated with continuous-flow left ventricular assist device. The New England journal of medicine 361: 2241-2251.
7. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, et al. (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113: 1807-1816.
8. Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, et al. (2006) Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 113: 2733-2743.
9. Geisler T, Fekecs L, Wurster T, Chiribiri A, Schuster A, et al. (2011) Association of platelet-SDF-1 with hemodynamic function and infarct size using cardiac MR in patients with AMI. European journal of radiology.
10. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, et al. (2006) Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. Journal of the American College of Cardiology 48: 1977-1985.
11. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, et al. (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. Journal of the American College of Cardiology 56: 867-874.
12. Grun S, Schumm J, Greulich S, Wagner A, Schneider S, et al. (2012) Long-Term Follow-Up of Biopsy-Proven Viral Myocarditis: Predictors of Mortality and Incomplete Recovery. Journal of the American College of Cardiology.
13. Felker GM, Shaw LK, O'Connor CM, (2002) A standardized definition of ischemic cardiomyopathy for use in clinical research. Journal of the American College of Cardiology 39: 210-218.
14. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European heart journal 29: 2388-2442.
15. Ordovas KG, Higgins CB, (2011) Delayed contrast enhancement on MR images of myocardium: past, present, future. Radiology 261: 358-374.
16. Camici PG, Prasad SK, Rimoldi OE, (2008) Stunning, hibernation, and assessment of myocardial viability. Circulation 117: 103-114.
17. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, et al. (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. The New England journal of medicine 343: 1445-1453.
18. Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, et al. (2008) Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. Journal of the American College of Cardiology 51: 2414-2421.
19. Lehrke S, Lossnitzer D, Schob M, Steen H, Merten C, et al. (2011) Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 97: 727-732.
20. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, et al. (2008) Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. Journal of the American College of Cardiology 51: 1369-1374.
21. Appelbaum E, Maron BJ, Adabag S, Hauser TH, Lesser JR, et al. (2012) Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circulation Cardiovascular imaging 5: 78-85.
22. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, et al. (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology 56: 875-887.
23. Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, et al. (2005) Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. Journal of the American College of Cardiology 45: 1104-1108.
24. Ramani K, Judd RM, Holly TA, Parrish TB, Rigolin VH, et al. (1998) Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation 98: 2687-2694.
25. Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, et al. (2001) Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation 104: 1101-1107.
26. Ingkanisorn WP, Rhoads KL, Aletras AH, Kellman P, Arai AE, (2004) Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. Journal of the American College of Cardiology 43: 2253-2259.
27. Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, et al. (2006) Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 114: 32-39.
28. Michels VV, Driscoll DJ, Miller FA, Olson TM, Atkinson EJ, et al. (2003) Progression of familial and non-familial dilated cardiomyopathy: long term follow up. Heart 89: 757-761.
29. Miller WL, Hartman KA, Burritt MF, Burnett JC Jr, Jaffe AS, (2007) Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies. Clinical cardiology 30: 245-250.
30. Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, et al. (2008) Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA: the journal of the American Medical Association 299: 2656-2666.
31. Bauer A, Watanabe MA, Barthel P, Schneider R, Ulm K, et al. (2006) QRS duration and late mortality in unselected post-infarction patients of the revascularization era. European heart journal 27: 427-433.
32. Hsia HH, Marchlinski FE, (2002) Characterization of the electroanatomic substrate for monomorphic ventricular tachycardia in patients with nonischemic cardiomyopathy. Pacing and clinical electrophysiology: PACE 25: 1114-1127.
33. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, et al. (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. The New England journal of medicine 342: 1077-1084.
34. Bauer A, Barthel P, Schneider R, Ulm K, Muller A, et al. (2009) Improved Stratification of Autonomic Regulation for risk prediction in post-infarction patients with preserved left ventricular function (ISAR-Risk). European heart journal 30: 576-583.
35. Bauer A, Kantelhardt JW, Barthel P, Schneider R, Makikallio T, et al. (2006) Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 367: 1674-1681.
36. Bauer A, Malik M, Schmidt G, Barthel P, Bonnemeier H, et al. (2008) Heart rate turbulence: standards of measurement, physiological interpretation, and clinical use: International Society for Holter and Noninvasive Electrophysiology Consensus. Journal of the American College of Cardiology 52: 1353-1365.
37. Verrier RL, Klingenheben T, Malik M, El-Sherif N, Exner DV, et al. (2011) Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility-consensus guideline by International Society for Holter and Noninvasive Electrocardiology. Journal of the American College of Cardiology 58: 1309-1324.